Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
  • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
  • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Definitions

• This invention relates to novel compounds having useful pharmacological properties, to a process for their
• EP-A-337547 (Merck Sharp and Dohme Limited), EP-A-329932
• Patents 4920219 and 4920227 disclose classes of compounds which have a saturated azabicyclic moiety, such as tropanyl, granatyl or quinuclidinyl, and are 5-HT 3 receptor antagonists.
• X is a phenyl group or a monocyclic 5 or 6 membered
• heteroaryl group either of which group is optionally fused to a saturated or unsaturated 5-7 membered carbocyclic or heterocyclic ring;
• A is a linking moiety
• R is hydrogen or methyl
• X may be unsubstituted or substituted, usually by one or more substituents selected from halogen, C 1 - 6 alkoxy, C 1-6 alkylthic, C 1- 6 alkyl, hydroxy, amino, C 1-6 alkylamino, C 1 -7 alkanoylamino, or two substituents on X (when fused), may be linked to form a saturated or unsaturated optionally
• Heteroatoms for heteroaryl and heterocyclic groups are selected from oxygen, nitrogen and sulphur.
• Halo includes bromo, chloro and fluoro.
• X may be joined to A by an aromatic carbon atom, or (when X is fused), by a carbocyclic ring carbon atom, or by a heterocyclic ring carbon or nitrogen atom. When X is fused, and A is attached at an aromatic carbon atom, it is
• Suitable examples of X are as described in the
• Suitable examples of A include CONH (amide), COO (ester), NHCONH (ureide), CONHCONH (extended ureide), or a group of structure (j):
• the present invention provides a compound of formula (IA), or a pharmaceutically acceptable salt thereof:
• Y is NH or O (or is joined to R 10 as defined below);
• X 1 is a group of formula (a), (b), (c), (d), (e), (f), (g)
• R a to R e and R g to R h are selected from hydrogen, halogen or hydroxy
• R 1 is hydrogen and R 2 is hydrogen or C 1 -4 alkyl
• R 1 and R 2 together are a bond
• R 3 to R 7 are independently hydrogen or C 1 -6 alkyl
• R 4 together with R 2 may be C 2-7 polymethylene or C 2 - 6
• R 8 and R 9 are independently selected from hydrogen or
• R 11 is hydrogen, halo, C 1-6 alkoxy or C 1-6 alkyl
• R 10 and R 1 1 are joined to form -OCH (R 15 R 16 )-E- wherein E is
• R 12 is
• R 13 is halo, C 1-6 alkyl, C 1-6 alkoxy or C 1-6 alkylthio
• R 14 is hydrogen or C 1-6 alkyl
• CO-Y- is in the 1-position and either R 15 is in the
• R 15 is in the 4-position and is hydrogen, halogen, CF 3 , C 1- 6 alkyl , C 1-7 acyl , C 1- 7 acylamino , phenyl optionally substituted by one or two C 1-6 alkyl, C 1-6 alkoxy or halogen groups, or amino, aminocarbonyl or aminosulphonyl, optionally substituted by one or two C 1-6 alkyl or C 3-8 cycloalkyl groups or by C 4-5 polymethylene or by phenyl, C 1-6 alkylsulphonyl, C 1-6 alkylsulphinyl , C 1- 6 alkoxy, C 1 -6 alkylthio, hydroxy or nitro; or
• CO-Y- is in the 3-position and either R 15 is in the
• R 15 is in the 4-position and is hydrogen or C 1-6 alkoxy;
• L is CH or N
• moieties in alkyl or alkyl containing groups in Z or in R 1 to R 15 include methyl, ethyl, n- and iso-propyl, n-, iso-, sec- and tert-butyl, preferably methyl.
• Cycloalkyl moieties include C 3 , C 4 , C 5 , C 6 , C 7 and C 8 cycloalkyl.
• Halo moieties include fluoro, chloro, bromo and iodo.
• R 2 and R 4 or R 8 and R 9 when joined include C 2 , C 3 , C 4 , C 5 or C 6 polymethylene, preferably C 2 , C 3 , C 4 or C 5 Polymethylene .
• R a to R e and R g to R h are preferably selected from hydrogen, fluoro, chloro and hydroxy, most preferably hydrogen.
• R b may be 5-, 6- or 7-chloro or fluoro.
• R 1 and R 3 is preferably hydrogen and one or both of R 2 and R 4 (most preferably both) are alkyl groups, such as methyl, or are joined to form C 2-7 polymethylene; or when one of R 2 and R 4 is hydrogen, the other is preferably ethyl or n- or iso- propyl.
• R 5 is preferably hydrogen or a methyl or ethyl group.
• R 7 is preferably methyl.
• R 8 and R 9 are preferably both methyl groups.
• R 10 is C 1-6 alkoxy or is joined to Y
• R 12 is preferably amino and R 13 is preferably chloro or bromo, most preferably chloro.
• R 10 is preferably methoxy when C 1-6 alkoxy.
• R 11 and R 13 are preferably chloro or methyl and R 10 is preferably hydrogen.
• R 14 is preferably hydrogen or methyl.
• R 15 when in the 4-position, include the following: hydrogen, chloro, bromo, methyl, ethyl, amino, methylamino, dimethylamino, phenyl, C 1 _ 4 alkanoylamino such as formylamino, acetylamino, propionylamino, n- and
• aminosulphonyl optionally substituted by one or two methyl, ethyl, n- or iso-propyl, n-, sec-, iso- or tert-butyl or phenyl groups; nitro, n- and iso-propoxy, methylthio, ethylthio, n- and iso-propylthio, hydroxy, methylsulphonyl and ethylsulphonyl or when R 15 is in the 3-position suitable examples, include the following groups, hydrogen, methyl, ethyl, n- or iso-propyl, methoxy, and ethoxy.
• R 15 when in the 1-position include hydrogen, methyl, ethyl, n- or iso- propyl, or when R 15 is in the 4-position, suitable examples include the following: hydrogen, methoxy and ethoxy.
• Preferred R 15 groups, in any of the positions specified above, include hydrogen, methyl and methoxy.
• CO-Y- is preferably in the 1-position.
• Y is preferably NH.
• the pharmaceutically acceptable salts of the compounds of the formula (I) include acid addition salts with
• Examples of pharmaceutically acceptable salts include quaternary derivatives of the compounds of formula (I) such as the compounds quaternised by compounds R x -T wherein R x is C 1-6 alkyl, phenyl-C 1-6 alkyl or C 5 -7 cycloalkyl, and T is a radical corresponding to an anion of an acid.
• R ⁇ include methyl, ethyl and n- and iso-propyl; and benzyl and phenethyl.
• Suitable examples of T include halide such as chloride, bromide and iodide.
• Examples of pharmaceutically acceptable salts also include internal salts such as N-oxides.
• the compounds of the formula (I), their pharmaceutically acceptable salts, (including quaternary derivatives and N-oxides) may also form pharmaceutically acceptable
• X-CO-Y- in compounds of formula (I) may adopt an ⁇ or ⁇ or configuration with respect to Z.
• the compounds of formula (I) are prepared by linking
• azabicyclic side chain intermediates may be prepared from the corresponding ketones of formula (II) and (III):
• the ketones of the formula (II) may be prepared according to the method described by G. H. Dewar, R.T. Parfitt, L. Sheh; Eur. J. Med. Chem., 1985, 20 , 228, and the ketone of formula (III) may be prepared according to the method described in the Description 2 hereinafter.
• the compounds of the present invention are 5-HT 3 receptor antagonists and it is thus believed may generally be used in the treatment or prophylaxis of pain, emesis, CNS disorders and gastrointestinal disorders. Pain includes migraine, cluster headache, trigeminal neuralgia and visceral pain; emesis, includes, in particular, that of preventing vomiting and nausea associated with cancer therapy, post-operative emesis, and nausea associated with migraine.
• cancer therapy examples include that using cytotoxic agents, such as platinum complexes including cisplatin, and also doxorubicin and cyclophosphamide, particularly cisplatin; and also radiation treatment.
• CNS disorders include anxiety, psychosis, cognitive disorders such as senile dementia and age associated memory impairment (AAMI), and drug dependence.
• Gastrointestinal disorders include irritable bowel syndrome and diarrohea.
• 5-HT 3 receptor antagonists may also be of potential use in the treatment of obesity, arrhythmia, and/or disorders associated with myocardial instability.
• the invention also provides a pharmaceutical composition
• a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
• compositions are prepared by admixture and are usually adapted for oral or parenteral administration, and as such may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable and infusable solutions or suspensions or suppositories .
• Orally administrable compositions are preferred, since they are more convenient for general use.
• Tablets and capsules for oral administration are usually presented in a unit dose, and contain conventional
• excipients such as binding agents, fillers, diluents, tabletting agents, lubricants, disintegrants, colourants, flavourings, and wetting agents.
• the tablets may be coated according to well known methods in the art, for example with an enteric coating.
• Suitable fillers for use include cellulose, mannitol, lactose and other similar agents.
• Suitable disintegrants include starch, polyvinylpolypyrrolidone and starch
• Suitable lubricants include, for example, magnesium stearate.
• Suitable pharmaceutically acceptable wetting agents include sodium lauryl sulphate.
• Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs, or may be
• Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel or hydrogenated edible fats,
• suspending agents for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel or hydrogenated edible fats,
• emulsifying agents for example lecithin, sorbitan
• non-aqueous vehicles which may include edible oils, for example, almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.
• Oral liquid preparations are usually in the form of aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs or are presented as a dry product for reconstitution with water or other suitable vehicle before use.
• Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), preservatives, and flavouring or colouring agents.
• the oral compositions may be prepared by conventional methods of blending, filling or tabletting. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large
• fluid unit dose forms are prepared containing a compound of the present invention and a sterile vehicle.
• the compound depending on the vehicle and the concentration, can be either suspended or dissolved.
• Parenteral solutions are normally prepared by dissolving the compound in a vehicle and filter sterilising before filling into a suitable vial or ampoule and sealing.
• adjuvants such as a local anaesthetic, preservatives and buffering agents are also dissolved in the vehicle.
• the composition can be frozen after filling into the vial and the water removed under vacuum.
• Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilised by
• a surfactant or wetting agent is included in the composition to facilitate uniform
• the invention further provides a method of treatment or prophylaxis of pain, emesis, CNS disorders and/or
• gastrointestinal disorders in mammals such as humans, which comprises the administration of an effective amount of a compound of the formula (I) or a pharmaceutically acceptable salt thereof.
• a unit dose for a 70kg adult will normally contain 0.05 to 1000mg for example 0.5 to 500mg, of the compound of the invention.
• Unit doses may be administered once or more than once a day, for example, 2, 3 or 4 times a day, more usually 1 to 3 times a day, that is in the range of approximately 0.0001 to 50mg/kg/day, more usually 0.0002 to 25 mg/kg/day.
• the invention also provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for use as an active therapeutic substance, in particular for use in the treatment of pain, emesis, CNS disorders and/or
• the oxime (1.97g, 0.012mol) was dissolved in amyl alcohol (80ml) and heated to reflux under N 2 .
• Sodium metal (6.5g, 0.28mol) was added portionwise over a 20 minute period and heating was continued for a further 1.5h.
• the solution was allowed to cool slightly and water (20ml) was added
• Compounds are given intravenously and the concentration required to reduce the 5-HT-evoked response to 50% of the control response (ED 50 ) is then determined.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Applications Claiming Priority (4)

Publications (1)

Family

ID=26298233

Family Applications (1)

Country Status (4)

Families Citing this family (18)

Family Cites Families (1)

• 1992
  • 1992-01-09 JP JP4502573A patent/JPH06506443A/ja active Pending
  • 1992-01-09 AU AU11612/92A patent/AU1161292A/en not_active Abandoned
  • 1992-01-09 EP EP19920902098 patent/EP0566609A1/de not_active Withdrawn
  • 1992-01-09 WO PCT/GB1992/000050 patent/WO1992012149A1/en not_active Application Discontinuation

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events